Prenatal Gene Therapy via LNPs Shows Promise in Model of Neurodevelopmental Disorder
The vehicles that deliver gene editing cargo to the body’s cells can be toxic, complicating gene therapies, particularly those addressed to brain cells of developing fetuses. Less toxic carriers, however, are being developed by...
Antibiotic for liver disease linked to emergence of antimicrobial resistant superbug
An international team of researchers has found that an antibiotic commonly prescribed for patients with liver disease, called rifaximin, has led to the global emergence of an almost untreatable form of the antimicrobial resistant...
New drug TYRA-300 shows effectiveness in treating metastatic bladder cancer
Patients with advanced bladder cancer that had spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300. The drug targets changes in...
Rentschler Headquarters Begins Construction of Buffer Media Station
CDMO Rentschler Biopharma began construction of a new buffer media station at its company headquarters in Laupheim, Germany. The facility aims to further increase production efficiency and modernize the site, ensuring that the evolving...
Electric skin patch offers drug-free solution to bacterial infections
Using a few zaps of electricity to the skin, researchers can stop bacterial infections without using any drugs. For the first time, researchers designed a skin patch that uses imperceptible electric currents to control...
PIONEER software breaks down barriers in protein-protein interaction research
Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool is called PIONEER...
Nanobody-Adorned IgMs Target Viral Epitopes, Block Mutational Escape
Scientists headed by a team at the Icahn School of Medicine at Mount Sinai have developed an antibody-based platform, which they’ve called adaptive multi-epitope targeting with enhanced avidity (AMETA), to address a key challenge...
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for...
Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate. The...
Proteomics Could Go Ion-Free with “Fingerprinted” NEMS-MS
Ordinary mass spectrometers blast analytes into ionized fragments. But mass spectrometers that incorporate resonator-based detectors don’t blast anything. They keep analytes intact, potentially simplifying the identification of molecules in a sample. However, the key...
Seaport Eyes Platform, Pipeline Growth with $225M Series B
Daphne Zohar, founder and CEO of Seaport Therapeutics
Seaport Therapeutics said today it has closed on an oversubscribed $225 million Series B financing, with the proceeds set to be used toward enhancing its Glyph technology...
